Hybrid modeling for biopharmaceutical processes: advantages, opportunities, and implementation
Frontiers in Chemical Engineering, 2023 Process models are mathematical formulations (essentially a set of equations) that try to represent the real system/process in a digital or virtual form.
Harini Narayanan +5 more
doaj +2 more sources
Biopharmaceutical benchmarks 2022
Nature Biotechnology, 2022 Monoclonal antibodies as a group continue to lead biopharmaceuticals in numbers of approvals and sales, although COVID-19 vaccines shot to the top of the list of highest-grossing individual products.
G. Walsh, Eithne Walsh
semanticscholar +3 more sources
Occupational hygiene risk assessment at light speed—a study for protecting worker health and safety in the biopharmaceutical industry [PDF]
Frontiers in Public HealthBackgroundHazardous substances are ubiquitous in the workplace and improperly controlled exposure may result in severe illness and death. Occupational exposure models can be used to predict the level of exposure workers may experience while performing ...
Paul Kayser +3 more
doaj +2 more sources
Biopharmaceutical benchmarks 2018 [PDF]
Nature Biotechnology, 2018 Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.
G. Walsh
semanticscholar +3 more sources
Progress in biopharmaceutical development [PDF]
Biotechnology and Applied Biochemistry, 2017 Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine.
Małgorzata Kęsik-Brodacka
semanticscholar +4 more sources
Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
mAbs, 2020 This study aims to benchmark and analyze the process development and manufacturing costs across the biopharmaceutical drug development cycle and their contribution to overall research and development (R&D) costs.
Suzanne S. Farid +4 more
doaj +2 more sources
Biopharmaceutical benchmarks 2014
Nature Biotechnology, 2014 Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.
G. Walsh
semanticscholar +4 more sources
Identification of Existing Gaps to Complete Technological Catch-up in the Iranian biopharmaceutical industry: A Comparative Study Approach [PDF]
بهبود مدیریت, 2022 Technological catch-up is a very complex and time-consuming process that requires all kinds of capabilities to be acquired by the latercomer firms in order to successfully complete the various stages.
Ahmad Jafarnejad Chaghooshi +3 more
doaj +1 more source
Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics
Frontiers in Molecular Biosciences, 2022 Biopharmaceuticals such as monoclonal antibodies are required to be rigorously characterized using a wide range of analytical methods. Various material properties must be characterized and well controlled to assure that clinically relevant features and ...
Katharina Yandrofski +12 more
doaj +1 more source
Plant-based biopharmaceutical engineering
Nature Reviews Bioengineering, 2023 Plants can be engineered to recombinantly produce high-quality proteins such as therapeutic proteins and vaccines, also known as molecular farming. Molecular farming can be established in various settings with minimal cold-chain requirements and could ...
Lukas Eidenberger +2 more
semanticscholar +1 more source